What it is
AOD-9604 is a growth-hormone fragment studied for lipid metabolism and body-fat research.
Evidence boundary
Investigational / limited human evidence.
Trial evidence
- PMID 24124033 — AOD-9604 does not influence the WADA hGH isoform immunoassay.
- PMID 25208511 — Detection and in vitro metabolism of AOD9604.
- PMID 25382550 — Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions.
- PMID 11713213 — The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–4 (titration) | 300 mcg | 6 U (0.06 mL) | Once daily | 2.1 mg/week |
| Weeks 5–12 (target) | 500 mcg | 10 U (0.1 mL) | Once daily | 3.5 mg/week |
Weeks 1–4 (titration)
- Dose
- 300 mcg
- Draw / measure
- 6 U (0.06 mL)
- Frequency
- Once daily
- Weekly total
- 2.1 mg/week
Weeks 5–12 (target)
- Dose
- 500 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- Once daily
- Weekly total
- 3.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
-
Light (250 mcg/day): Conservative starting dose for tolerability assessment.
-
Standard (500 mcg/day): Common research dose. Morning fasted dosing is common.
-
Higher (1000 mcg/day): Used in some Phase 2 trials. May produce a stronger lipolytic effect.
-
Timing: Pre-fasted morning injection followed by 30–60 min of light cardio amplifies the lipolytic window. Some protocols use an additional pre-workout dose.
-
Appetite and body composition
-
Tolerability
-
Injection-site reactions
Practical rules
- Keep the schedule tied to the collected notes, not a broad claim.
- Use calorie control and training if body-fat loss is the goal.
- Rotate sites.